In this phase 3b , multicentre , randomized , open-label study , patients with moderate-to-severe plaque psoriasis received etanercept 50 mg BIW for 12 weeks , and then were randomized to etanercept 50 mg BIW or 50 mg QW plus topical agent as needed to achieve static physician global assessment ( sPGA ) status of clear for 12 weeks .